Literature DB >> 15676047

Increased C-reactive protein in ACE-inhibitor-induced angioedema.

M Bas1, T K Hoffmann, H Bier, G Kojda.   

Abstract

AIMS: This study was designed to identify new factors which may contribute to angiotensin-converting-enzyme-inhibitor (ACEI)-induced angioedema.
METHODS: In a retrospective cohort study we examined 25 patients who used an ACEI and presented at our emergency room with acute angioedema as well as 18 patients with unknown cause of angioedema and a total of 21 patients on ACEI-therapy without previous angioedema. We measured markers of inflammation such as acute-phase proteins (C-reactive protein, fibrinogen), leukocyte count and body temperature.
RESULTS: The mean interval between initiation of ACEI treatment and first manifestation of angioedema was 35.8 +/- 5.3 months. During symptomatic angioedema, mean plasma levels of C-reactive protein and fibrinogen were significantly increased by 7.3-fold and 1.5-fold, respectively, while leukocyte count and body temperature were normal. These changes disappeared after successful treatment of angioedema and were not found in patients with angioedema of unknown cause and those receiving ACEI without having experienced angioedema.
CONCLUSION: Our findings demonstrate for the first time that ACEI-induced angioedema is associated with strongly increased plasma levels of CRP. We suggest that CRP is involved in the pathophysiology of ACEI-induced angioedema.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15676047      PMCID: PMC1884750          DOI: 10.1111/j.1365-2125.2004.02268.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  25 in total

1.  Dipeptidyl peptidase IV activity in patients with ACE-inhibitor-associated angioedema.

Authors:  Jean Lefebvre; Laine J Murphey; Tina V Hartert; Ru Jiao Shan; William H Simmons; Nancy J Brown
Journal:  Hypertension       Date:  2002-02       Impact factor: 10.190

2.  Effects of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists in rats with heart failure. Role of kinins and angiotensin II type 2 receptors.

Authors:  Y H Liu; X P Yang; V G Sharov; O Nass; H N Sabbah; E Peterson; O A Carretero
Journal:  J Clin Invest       Date:  1997-04-15       Impact factor: 14.808

3.  Angio-oedema in relation to treatment with angiotensin converting enzyme inhibitors.

Authors:  T Hedner; O Samuelsson; H Lunde; L Lindholm; L Andrén; B E Wiholm
Journal:  BMJ       Date:  1992-04-11

4.  Enalapril and hydrochlorothiazide in hypertensive Africans.

Authors:  A A Ajayi; E A Oyewo; G O Ladipo; A Akinsola
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

5.  Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men.

Authors:  P M Ridker; M Cushman; M J Stampfer; R P Tracy; C H Hennekens
Journal:  N Engl J Med       Date:  1997-04-03       Impact factor: 91.245

6.  Role of angiotensin II type 2 receptors and kinins in the cardioprotective effect of angiotensin II type 1 receptor antagonists in rats with heart failure.

Authors:  Yun-He Liu; Xiao-Ping Yang; Edward G Shesely; Steadman S Sankey; Oscar A Carretero
Journal:  J Am Coll Cardiol       Date:  2004-04-21       Impact factor: 24.094

7.  Angiotensin-converting enzyme inhibitor use is associated with reduced plasma concentration of C-reactive protein in patients with first-ever ischemic stroke.

Authors:  Mario Di Napoli; Francesca Papa
Journal:  Stroke       Date:  2003-11-06       Impact factor: 7.914

8.  Black Americans have an increased rate of angiotensin converting enzyme inhibitor-associated angioedema.

Authors:  N J Brown; W A Ray; M Snowden; M R Griffin
Journal:  Clin Pharmacol Ther       Date:  1996-07       Impact factor: 6.875

9.  Differential acute-phase response of rat kininogen genes involves type I and type II interleukin-6 response elements.

Authors:  H M Chen; W S Liao
Journal:  J Biol Chem       Date:  1993-12-05       Impact factor: 5.157

Review 10.  Drug-induced angioedema without urticaria.

Authors:  A Agostoni; M Cicardi
Journal:  Drug Saf       Date:  2001       Impact factor: 5.228

View more
  11 in total

1.  [Angiotensin-converting enzyme inhibitor induced angioedema : new therapy options].

Authors:  M Bas; G Kojda; K Stelter
Journal:  Anaesthesist       Date:  2010-10-06       Impact factor: 1.041

2.  Guidance for diagnosis and treatment of acute angioedema in the emergency department: consensus statement by a panel of Italian experts.

Authors:  Marco Cicardi; Paolo Bellis; Giuliano Bertazzoni; Mauro Cancian; Maurizio Chiesa; Paolo Cremonesi; Pietro Marino; Nicola Montano; Claudia Morselli; Francesco Ottaviani; Roberto Perricone; Massimo Triggiani; Andrea Zanichelli
Journal:  Intern Emerg Med       Date:  2013-09-04       Impact factor: 3.397

3.  Potential genetic risk factors in angiotensin-converting enzyme-inhibitor-induced angio-oedema.

Authors:  Murat Bas; Thomas K Hoffmann; Bernd Tiemann; Vu Thao-Vi Dao; Christos Bantis; Vera Balz; Hans-Jürgen Schultz-Coulon; Thomas Stark; Patrick Schuler; Jens Greve; Katrin Ivens; Henning Bier; Georg Kojda
Journal:  Br J Clin Pharmacol       Date:  2010-02       Impact factor: 4.335

4.  [Angioedema due to ACE inhibitors and AT(1) receptor antagonists].

Authors:  M-C Hellebrand; G Kojda; T K Hoffmann; M Bas
Journal:  Hautarzt       Date:  2006-09       Impact factor: 0.751

5.  [Angioneurotic edema of the head and neck in association with ACE inhibitors].

Authors:  L Wahbe; H-J Schultz-Coulon
Journal:  HNO       Date:  2007-09       Impact factor: 1.284

6.  C-reactive protein levels in hereditary angioedema.

Authors:  Z L M Hofman; A Relan; C E Hack
Journal:  Clin Exp Immunol       Date:  2014-07       Impact factor: 4.330

Review 7.  [Angioedema].

Authors:  H F Merk
Journal:  Hautarzt       Date:  2007-12       Impact factor: 0.751

Review 8.  "Nuts and Bolts" of Laboratory Evaluation of Angioedema.

Authors:  Henriette Farkas; Nóra Veszeli; Erika Kajdácsi; László Cervenak; Lilian Varga
Journal:  Clin Rev Allergy Immunol       Date:  2016-10       Impact factor: 8.667

9.  The Influence of ACE Inhibition on C1-Inhibitor: A Biomarker for ACE Inhibitor-Induced Angioedema?

Authors:  Janina Hahn; Melanie Nordmann-Kleiner; Christoph Bönner; Georg Kojda; Thomas K Hoffmann; Jens Greve
Journal:  Biomed Hub       Date:  2019-05-07

10.  Angioedema, ACE inhibitor and COVID-19.

Authors:  Ekjot Grewal; Bayu Sutarjono; Ibbad Mohammed
Journal:  BMJ Case Rep       Date:  2020-09-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.